Clinical Trials on Remission/Regression in Canada

Total 718 results

Eli Lilly and Company

Completed

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes (MOSAIc)

Diabetes Mellitus, Type 2

United States, Argentina, Brazil, Canada, China, Germany, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Puerto Rico, Russian Federation, Saudi Arabia, Spain, Turkey, United Arab Emirates, United Kingdom
Emory University
Crohn's and Colitis Foundation

Completed

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease (RS)

Crohn's Disease

United States, Canada
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Brainsway

Completed

Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)

Major Depressive Disorder, Recurrent, Unspecified | Major Depressive Disorder, Single Episode, Unspecified

United States, Canada, Germany, Israel
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Poland, Serbia, Russian Federation, Germany, Canada, France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (Pyxis)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Canada, Slovakia
Takeda
H. Lundbeck A/S

Completed

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Mexico, Canada
MedSIR
Eli Lilly and Company

Active, not recruiting

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL)

Breast Cancer Metastatic

Italy, Spain, Portugal
Alkermes, Inc.

Completed

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

Major Depressive Disorder

United States, Australia, Canada
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

Major Depressive Disorder

United States, Canada
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Spain, Canada, Puerto Rico, Croatia, Mexico
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Major Depressive Disorder

Finland, Sweden, Estonia, Bulgaria, United States, Canada, Germany, Korea, Republic of, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Ukraine, United Kingdom
GlaxoSmithKline

Completed

Study Of GW679769 In Major Depressive Disorder

Depressive Disorder, Major | Major Depressive Disorder (MDD)

United States, Canada
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

Major Depressive Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, United States, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Mexico, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Latvia, South Africa
Janssen Research & Development, LLC

Completed

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II)

Depressive Disorder, Major

United States, Belgium, Canada, Poland, France, Spain, Brazil, Lithuania, Czechia, Austria, Argentina, Turkey
Dendreon

Completed

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

Metastatic Androgen Independent Prostate Cancer

United States, Canada
Hoffmann-La Roche

Completed

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Major Depressive Disorder

United States, Germany, Austria, Russian Federation, Ukraine, Canada, Slovakia, South Africa
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Bayer

Completed

Depression Related Improvement With Vardenafil for Erectile Response (DRIVER)

Depression | Erectile Dysfunction

Italy, Spain, France, United States, Canada
AstraZeneca

Completed

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (ONYX)

Major Depressive Disorder

Sweden, Czech Republic, France, Germany, Poland, Romania, Finland, Norway, Belgium, Canada, Australia, South Africa
AbbVie

Completed

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Canada, Czechia, Finland, Poland, Puerto Rico, Serbia, Slovakia
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Study of Antidepressants in Parkinson's Disease (SAD-PD)

Depression | Parkinson Disease

United States, Puerto Rico, Canada
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
H. Lundbeck A/S

Completed

Real-life Effectiveness of Vortioxetine in Depression (RELIEVE)

Major Depressive Disorder

United States, Canada, France, Italy
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Fibromyalgia

Spain, United States, Canada, Italy
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Major Depressive Disorder

United States
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Pfizer

Completed

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Major Depressive Disorder

Canada, United States, Colombia, Croatia, Estonia, Finland, Poland, France, Slovakia, Chile, Latvia, Lithuania, Romania, South Africa
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Alkermes, Inc.

Completed

A Long-Term Safety Study of ALKS 5461

Major Depressive Disorder

United States, Canada, Germany, Puerto Rico, Bulgaria, Australia, Poland, Hungary
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Brazil, Spain, Argentina, United Kingdom, Sweden, Italy, Germany, France, Canada
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
AstraZeneca

Completed

Depressive Symptoms in Acute Manic Episode (MM1)

Bipolar Disorder

Spain
Takeda

Completed

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Treatment Outcome

United States, Canada
AstraZeneca

Completed

Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder (AMETHYST)

Major Depressive Disorder

United States, Russian Federation, United Kingdom, Romania, Canada, Slovakia, Bulgaria, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Fungal Infection | Neutropenia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent Childhood Acute Myeloid... and other conditions

United States, Canada, Puerto Rico
Mediti Pharma Inc.

Terminated

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Aggression | Dementia | Psychosis | Agitation | Alzheimer Dementia

United States, Canada
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Slovakia, Brazil, Poland, Argentina, Bulgaria, Czechia, South Africa, Canada, United Kingdom, France
Eli Lilly and Company

Terminated

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE-AD)

Alzheimer's Disease

United States, Australia, Canada, Japan
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia
Opexa Therapeutics, Inc.

Completed

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (Abili-T)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Disease Progression | Secondary Progressive Multiple Sclerosis | Brain Atrophy

United States, Canada
OPKO Health, Inc.
Elan Pharmaceuticals

Terminated

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Spain, United Kingdom

Clinical Trials on Remission/Regression in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations